Advertising Disclaimer
Published online February 11, 2008
PEDIATRICS Vol. 121 No. 3 March 2008, pp. e553-e560 (doi:10.1542/peds.2006-3632)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouissou, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouissou, F.
Related Collections
Right arrow Genitourinary Tract
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Prospective, Randomized Trial Comparing Short and Long Intravenous Antibiotic Treatment of Acute Pyelonephritis in Children: Dimercaptosuccinic Acid Scintigraphic Evaluation at 9 Months

François Bouissou, MDa, Caroline Munzer, PhDa, Stéphane Decramer, MDa, Bernard Roussel, MDb, Robert Novo, MDc, Denis Morin, MDd, Marie Pierre Lavocat, MDe, Claude Guyot, MDf, Sophie Taque, MDg, Michel Fischbach, MDh, Eric Ouhayoun, MDi on behalf of the French Society of Nuclear Medicine and Molecular Imaging, Chantal Loirat, MDj on behalf of the French Society of Pediatric Nephrology

a Néphrologie Pédiatrique, Hôpital des Enfants, Université Paul Sabathier, Centre Hospitalier Universitaire Purpan, Toulouse, France
b Néphrologie Pédiatrique, American Memorial Hospital, Centre Hospitalier Universitaire Reims, Beims, France
c Néphrologie Pédiatrique, Hôpital Jeanne de Flandre, Université Lille 2, Centre Hospitalier Régional Universitaire Lille, Lille, France
d Néphrologie Pédiatrique, Hôpital Arnaud de Villeneuve, Université Montpellier I, Centre Hospitalier Universitaire Montpellier, Montpellier, France
e Néphrologie Pédiatrique, Centre Hospitalier Universitaire Saint Etienne, Saint Etienne, France
f Néphrologie Pédiatrique, Hôpital Mère Enfant, Université de Nantes, Centre Hospitalier Universitaire de Nantes, Nantes, France
g Néphrologie Pédiatrique, Centre Hospitalier Universitaire Rennes, Rennes, France
h Néphrologie Pédiatrique, Hôpital Hautepierre, Université Louis Pasteur, Centre Hospitalier Universitaire Strasbourg, Strasbourg, France
i Médecine Nucléaire, Université Paul Sabathier, Centre Hospitalier Universitaire Purpan Toulouse, Toulouse, France
j Service de Néphrologie, Faculté de Médecine Denis Diderot, Université Paris VII, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France

OBJECTIVE. We report a prospective, randomized, multicenter trial that compared the effect of 3 vs 8 days of intravenous ceftriaxone treatment on the incidence of renal scarring at 6 to 9 months of follow-up in 383 children with a first episode of acute pyelonephritis.

METHODS. After initial treatment with intravenous netilmicin and ceftriaxone, patients were randomly assigned to either 5 days of oral antibiotics (short intravenous treatment) or 5 days of intravenous ceftriaxone (long intravenous treatment). Inclusion criteria were age 3 months to 16 years and first acute pyelonephritis episode, defined by fever of >38.5°C, C-reactive protein level of >20 mg/L, and bacteriuria at >105/mL. All patients underwent 99m technetium-dimercaptosuccinic acid scintigraphy 6 to 9 months after inclusion. A total of 548 children were included, 48 of whom were secondarily excluded and 117 of whom were lost to follow-up or had incomplete data; therefore, 383 children were eligible, 205 of them in the short intravenous treatment group and 178 in the long intravenous treatment group.

RESULTS. At inclusion, median age was 15 months, median duration of fever was 43 hours, and median C-reactive protein level was 122 mg/L. A total of 37% (143 of 383) of patients had a vesicoureteral reflux grades 1 to 3. Patient characteristics at inclusion were similar in both groups, except for a significantly higher proportion of girls in the short intravenous treatment group. The frequency of renal scars at scintigraphy was similar in both groups. Multivariate analysis demonstrated that renal scars were significantly associated with increased renal height at initial ultrasound and with the presence of grade 3 vesicoureteric reflux.

CONCLUSIONS. The incidence of renal scars was similar in patients who received 3 days compared 8 days of intravenous ceftriaxone. Increased renal height at initial ultrasound examination and grade 3 vesicoureteric reflux were significant risk factors for renal scars.


Key Words: children • acute pyelonephritis • antibiotics • DMSA scintigraphy

Abbreviations: APN—acute pyelonephritis • DMSA—dimercaptosuccinic acid • VUR—vesicoureteral reflux • CRP—C-reactive protein • 99mTc—99m technetium • OR—odds ratio


Accepted Aug 1, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JWatch PediatricsHome page
Duration of IV Antibiotic Treatment for Children with Pyelonephritis
Journal Watch Pediatrics and Adolescent Medicine, March 26, 2008; 2008(326): 2 - 2.
[Full Text]